• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical lymphoma & myeloma >CD43 Expression is an adverse prognostic factor in diffuse large B-cell lymphoma
【24h】

CD43 Expression is an adverse prognostic factor in diffuse large B-cell lymphoma

机译：CD43表达是弥漫性大B细胞淋巴瘤的不良预后因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: CD43 is a transmembrane glycoprotein expressed in different hematopoietic cells, including some subsets of B lymphocytes. About a quarter of diffuse large B-cell lymphomas (DLBCLs) express CD43, but its prognostic significance is unknown. Patients and Methods: We analyzed the prognostic effect of immunohistochemically determined CD43 expression in 119 patients with newly diagnosed DLBCL. All were treated with CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone)-like chemotherapy, 57 without and 62 with rituximab. Results: A total of 31 DLBCL cases (26%) expressed CD43. Patients with CD43+ and CD43- lymphomas did not differ regarding sex, International Prognostic Index (IPI) factors and score, rituximab treatment, presence of bulky disease, or germinal center subtype. Median follow-up was 45 months. Patients with CD43+ DLBCL had significantly lower complete response rates (59% vs. 80%; P = .019), 2-year event-free survival (EFS) rates (34% vs. 64%; P = .003), and overall survival (OS) rates (45% vs. 76%; P = .002). The prognostic significance of CD43 expression was retained in multivariate analysis (relative risk [RR] 2.04; P = .013 for EFS; RR 2.17; P = .016 for OS). In subgroup analysis, the effect of CD43 expression was significant in patients treated with rituximab and those with low IPI, whereas it was not reached in patients treated without rituximab. The effect was not observed in patients with high IPI. Conclusion: These results indicate that CD43 expression is an important independent adverse prognostic factor in DLBCL.
机译：背景：CD43是一种跨膜糖蛋白，表达于不同的造血细胞中，包括某些B淋巴细胞亚群。大约四分之一的弥漫性大B细胞淋巴瘤（DLBCL）表达CD43，但其预后意义尚不清楚。患者和方法：我们分析了119例新诊断DLBCL患者的免疫组化测定CD43表达的预后。所有患者均接受CHOP（环磷酰胺/阿霉素/长春新碱/泼尼松）样化疗，无化疗57例，利妥昔单抗62例。结果：总共31例DLBCL病例（26％）表达CD43。 CD43 +和CD43-淋巴瘤患者在性别，国际预后指数（IPI）因素和评分，利妥昔单抗治疗，存在大块疾病或生发中心亚型方面无差异。中位随访时间为45个月。 CD43 + DLBCL患者的完全缓解率（59％vs. 80％; P = .019），2年无事件生存（EFS）率（34％vs. 64％; P = .003）和更低总生存（OS）率（45％对76％; P = 0.002）。 CD43表达的预后意义在多变量分析中得以保留（相对危险度[RR] 2.04; EFS为P = 0.013; OS为RR 2.17; P = .016）。在亚组分析中，CD43表达的影响在接受利妥昔单抗治疗的患者和IPI低的患者中显着，而未接受利妥昔单抗治疗的患者则未达到。在高IPI患者中未观察到效果。结论：这些结果表明CD43表达是DLBCL中重要的独立不良预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号